Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema

Plus, news about Keymed Biosciences, Ouro Medicines, Recode, Intellia, Quell, VBI Vaccines and Zai Lab: Aclaris adds two anti-TSLP programs, seeks $80M: The new pipeline candidates come from a partnership with ...